Several preclinical and clinical studies have been carried out with the first approved human gene therapy product, Glybera, an AAV1-based gene therapy that has been developed for the treatment of patients with lipoprotein lipase (LPL) deficiency. This evidence concerns the gene LPL and hyperinsulinemic hypoglycemia, familial, 4.